163 related articles for article (PubMed ID: 35767735)
1. The identification of TCF1+ progenitor exhausted T cells in THRLBCL may predict a better response to PD-1/PD-L1 blockade.
Tabanelli V; Melle F; Motta G; Mazzara S; Fabbri M; Agostinelli C; Calleri A; Del Corvo M; Fiori S; Lorenzini D; Cesano A; Chiappella A; Vitolo U; Derenzini E; Griffin GK; Rodig SJ; Vanazzi A; Sabattini E; Tarella C; Sapienza MR; Pileri SA
Blood Adv; 2022 Aug; 6(15):4634-4644. PubMed ID: 35767735
[TBL] [Abstract][Full Text] [Related]
2. Immune Profiling and Quantitative Analysis Decipher the Clinical Role of Immune-Checkpoint Expression in the Tumor Immune Microenvironment of DLBCL.
Xu-Monette ZY; Xiao M; Au Q; Padmanabhan R; Xu B; Hoe N; Rodríguez-Perales S; Torres-Ruiz R; Manyam GC; Visco C; Miao Y; Tan X; Zhang H; Tzankov A; Wang J; Dybkær K; Tam W; You H; Bhagat G; Hsi ED; Ponzoni M; Ferreri AJM; Møller MB; Piris MA; van Krieken JH; Winter JN; Westin JR; Pham LV; Medeiros LJ; Rassidakis GZ; Li Y; Freeman GJ; Young KH
Cancer Immunol Res; 2019 Apr; 7(4):644-657. PubMed ID: 30745366
[TBL] [Abstract][Full Text] [Related]
3. Matched-pair analysis comparing the outcomes of T cell/histiocyte-rich large B cell lymphoma and diffuse large B cell lymphoma in patients treated with rituximab-CHOP.
Kim YS; Ji JH; Ko YH; Kim SJ; Kim WS
Acta Haematol; 2014; 131(3):156-61. PubMed ID: 24192382
[TBL] [Abstract][Full Text] [Related]
4. Immunophenotypic Characterization and Purification of Neoplastic Cells from Lymph Nodes Involved by T-Cell/Histiocyte-rich Large B-cell Lymphoma by Flow Cytometry and Flow Cytometric Cell Sorting.
Glynn E; Fromm JR
Cytometry B Clin Cytom; 2020 Jan; 98(1):88-98. PubMed ID: 31254446
[TBL] [Abstract][Full Text] [Related]
5. Array comparative genomic hybridization reveals similarities between nodular lymphocyte predominant Hodgkin lymphoma and T cell/histiocyte rich large B cell lymphoma.
Hartmann S; Döring C; Vucic E; Chan FC; Ennishi D; Tousseyn T; de Wolf-Peeters C; Perner S; Wlodarska I; Steidl C; Gascoyne RD; Hansmann ML
Br J Haematol; 2015 May; 169(3):415-22. PubMed ID: 25644177
[TBL] [Abstract][Full Text] [Related]
6. Macrophages in T cell/histiocyte rich large B cell lymphoma strongly express metal-binding proteins and show a bi-activated phenotype.
Hartmann S; Tousseyn T; Döring C; Flüchter P; Hackstein H; Herreman A; Ponzoni M; de Wolf-Peeters C; Facchetti F; Gascoyne RD; Küppers R; Steidl C; Hansmann ML
Int J Cancer; 2013 Dec; 133(11):2609-18. PubMed ID: 23686423
[TBL] [Abstract][Full Text] [Related]
7. Prognostic implications of the tumor immune microenvironment and immune checkpoint pathway in primary central nervous system diffuse large B-cell lymphoma in the North Indian population.
Parkhi M; Chatterjee D; Bal A; Vias P; Yadav BS; Prakash G; Gupta SK; Radotra BD
APMIS; 2022 Feb; 130(2):82-94. PubMed ID: 34862664
[TBL] [Abstract][Full Text] [Related]
8. MiR155 sensitized B-lymphoma cells to anti-PD-L1 antibody via PD-1/PD-L1-mediated lymphoma cell interaction with CD8+T cells.
Zheng Z; Sun R; Zhao HJ; Fu D; Zhong HJ; Weng XQ; Qu B; Zhao Y; Wang L; Zhao WL
Mol Cancer; 2019 Mar; 18(1):54. PubMed ID: 30925928
[TBL] [Abstract][Full Text] [Related]
9. Prognostic and clinicopathological significance of PD-1/PD-L1 expression in the tumor microenvironment and neoplastic cells for lymphoma.
Xie M; Huang X; Ye X; Qian W
Int Immunopharmacol; 2019 Dec; 77():105999. PubMed ID: 31704289
[TBL] [Abstract][Full Text] [Related]
10. PD-1/PD-L1 Pathway and Its Blockade in Patients with Classic Hodgkin Lymphoma and Non-Hodgkin Large-Cell Lymphomas.
Xie W; Medeiros LJ; Li S; Yin CC; Khoury JD; Xu J
Curr Hematol Malig Rep; 2020 Aug; 15(4):372-381. PubMed ID: 32394185
[TBL] [Abstract][Full Text] [Related]
11.
Godfrey J; Tumuluru S; Bao R; Leukam M; Venkataraman G; Phillip J; Fitzpatrick C; McElherne J; MacNabb BW; Orlowski R; Smith SM; Kline J
Blood; 2019 May; 133(21):2279-2290. PubMed ID: 30910787
[TBL] [Abstract][Full Text] [Related]
12. Spatial signatures identify immune escape via PD-1 as a defining feature of T-cell/histiocyte-rich large B-cell lymphoma.
Griffin GK; Weirather JL; Roemer MGM; Lipschitz M; Kelley A; Chen PH; Gusenleitner D; Jeter E; Pak C; Gjini E; Chapuy B; Rosenthal MH; Xu J; Chen BJ; Sohani AR; Lovitch SB; Abramson JS; Ishizuka JJ; Kim AI; Jacobson CA; LaCasce AS; Fletcher CD; Neuberg D; Freeman GJ; Hodi FS; Wright K; Ligon AH; Jacobsen ED; Armand P; Shipp MA; Rodig SJ
Blood; 2021 Mar; 137(10):1353-1364. PubMed ID: 32871584
[TBL] [Abstract][Full Text] [Related]
13. PD-1 expression on tumour-infiltrating cells is a prognostic factor for relapsed or refractory diffuse large B-cell lymphoma.
Wada F; Kamijo K; Shimomura Y; Yamashita D; Hara S; Ishikawa T
Immunology; 2024 Feb; 171(2):224-234. PubMed ID: 37904615
[TBL] [Abstract][Full Text] [Related]
14. Clinical features and survival of patients with T-cell/histiocyte-rich large B-cell lymphoma: analysis of the National Cancer Data Base.
Ollila TA; Reagan JL; Olszewski AJ
Leuk Lymphoma; 2019 Dec; 60(14):3426-3433. PubMed ID: 31287335
[TBL] [Abstract][Full Text] [Related]
15. Expression and clinical value of programmed cell death-ligand 1 (PD-L1) in diffuse large B cell lymphoma: a retrospective study.
Hu LY; Xu XL; Rao HL; Chen J; Lai RC; Huang HQ; Jiang WQ; Lin TY; Xia ZJ; Cai QQ
Chin J Cancer; 2017 Dec; 36(1):94. PubMed ID: 29246182
[TBL] [Abstract][Full Text] [Related]
16. Genomic stratification based on microenvironment immune types and PD-L1 for tailoring therapeutic strategies in bladder cancer.
Lyu X; Wang P; Qiao Q; Jiang Y
BMC Cancer; 2021 May; 21(1):646. PubMed ID: 34059019
[TBL] [Abstract][Full Text] [Related]
17. T cell/histiocyte-rich large B-cell lymphoma: an update on its biology and classification.
Tousseyn T; De Wolf-Peeters C
Virchows Arch; 2011 Dec; 459(6):557-63. PubMed ID: 22081105
[TBL] [Abstract][Full Text] [Related]
18. Nodular lymphocyte predominant hodgkin lymphoma and T cell/histiocyte rich large B cell lymphoma--endpoints of a spectrum of one disease?
Hartmann S; Döring C; Jakobus C; Rengstl B; Newrzela S; Tousseyn T; Sagaert X; Ponzoni M; Facchetti F; de Wolf-Peeters C; Steidl C; Gascoyne R; Küppers R; Hansmann ML
PLoS One; 2013; 8(11):e78812. PubMed ID: 24244368
[TBL] [Abstract][Full Text] [Related]
19. Characterisation of tumour microenvironment and immune checkpoints in primary central nervous system diffuse large B cell lymphomas.
Alame M; Pirel M; Costes-Martineau V; Bauchet L; Fabbro M; Tourneret A; De Oliveira L; Durand L; Roger P; Gonzalez S; Cacheux V; Rigau V; Szablewski V
Virchows Arch; 2020 Jun; 476(6):891-902. PubMed ID: 31811434
[TBL] [Abstract][Full Text] [Related]
20. Understanding Immune Evasion and Therapeutic Targeting Associated with PD-1/PD-L1 Pathway in Diffuse Large B-cell Lymphoma.
Song MK; Park BB; Uhm J
Int J Mol Sci; 2019 Mar; 20(6):. PubMed ID: 30884772
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
